In spite of the undoubtedly improved outcome in the rituximab era, there is not evidence as yet that immunochemotherapy will eventually cure a significant proportion of patients with follicular lymphoma (FL). Stem cell transplantation (SCT) has been explored with the aim of improving the clinical outcome of FL patients and, hopefully, to offer the chance of cure. Several randomized studies have evaluated the role of autologous SCT (auto-SCT), both in first or second remission, and showed an improved progression-free survival (PFS) compared with conventional chemotherapy, but with no definitive benefit in terms of overall survival (OS). 1 The procedure is well tolerated with a low non-relapse mortality (NRM) of around 5%. Although a few series with a very long follow-up suggest the existence of a plateau in the PFS curve and, hence, that cure may be possible, 2 many patients will eventually relapse.
In contrast, myeloablative allogeneic SCT (allo-SCT) can result in long-term disease control owing, in part, to the Table 1 Patients' baseline characteristics at the time of RIC allo-SCT according to GVHD prophylaxis (ATG vs alemtuzumab vs no TCD) graft-versus-lymphoma (GVL) effect, but is associated with a NRM in excess of 30% owing to direct conditioning regimen toxicity and graft-versus-host disease (GVHD). 3 As a result, reduced-intensity conditioning (RIC) regimens were devised to take advantage of the GVL effect while reducing the toxicity of conventional regimens. 4 However, there is still much debate with regard to the most appropriate RIC regimen for these patients. Furthermore, RIC regimens possibly have less direct toxicity compared with myeloablative regimens, but GVHD still remains a significant cause of morbidity and mortality in this population. Some cooperative groups have added alemtuzumab or antithymocyte globulin (ATG) to the conditioning regimen to deplete recipient and incoming donor T cells and provide sustained engraftment while reducing GVHD rates. This reduced GVHD rate is, however, counterbalanced by a delayed post-SCT immune reconstitution and a higher relapse rate. 5 Interestingly, a recent evidence-based review sponsored by the American Society of Blood and Marrow Transplantation identified the use of T-cell-depleted allo-SCT as one of the areas where research is most needed in patients with FL. 6 The aim of this study was to assess the role of in vivo T-cell depletion (TCD) in patients with advanced FL undergoing RIC allo-SCT from HLA-identical siblings. To have a homogeneous population and eliminate other confounding factors, we decided to include specifically FL patients conditioned with fludarabine plus an alkylating agent. Patients receiving transplants from alternative donors or conditioned with other agents (for example, low dose total body irradiation or BEAM (BCNU, Etoposide, Ara-C, Melphalan) chemotherapy) were specifically excluded. Patients undergoing RIC allo-SCT in the context of tandem transplantation programs or whose hematopoietic cell graft was manipulated in vitro were also excluded.
For the purpose of this study, they were divided into 46 (28%) patients who received ATG, 42 (26%) who received alemtuzumab and 76 (46%) who did not receive any of these agents (that is, no TCD). The standard alemtuzumab (Bayer Schering Pharma, Berlin, Germany) dose was 20 mg per day for 5 days (total dose, 100 mg), except 2, 1 and 4 patients who received a total dose of 50, 40 and 30 mg, respectively. The standard ATG Fresenius (Fresenius, Grafelfing, Germany) dose was 10 mg/kg daily for 4 days. Fourteen (30%) patients received thymoglobulin (Genzyme, Lyon, France) 2-2.5 mg/kg daily for 4 days instead of ATG Fresenius. Conditioning regimens comprised fludarabine 25-30 mg/m 2 daily for 5 days (total dose 125-150 mg/m 2 ) plus an alkylating agent. This was either melphalan 70 mg/m 2 daily for 2 days or 140 mg/m 2 for 1 day (total dose 140 mg/m 2 ), busulfan 3.2-4 mg/kg daily for 2 or 3 days (total dose 8-10 mg/kg depending on age) or cyclophosphamide 2-2.4 g/m 2 (total dose) divided into two or three doses. For additional GVHD prophylaxis, the great majority of patients received cyclosporine 3 mg/kg daily starting on day À1. Most patients in the ATG/alemtuzumab group were given cyclosporine alone, whereas the remaining patients were also given methotrexate (15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3 and þ 6) or mycophenolate mofetil (15 mg/kg per day twice daily from day þ 1) in addition to cyclosporine.
Median age at transplantation was 50 (range 29-64) years. Median follow-up was 50 (2-110) months for survivors and 37 (1-110) months for the entire cohort. There were no differences Table 2 Results after RIC allo-SCT according to GVHD prophylaxis (ATG vs alemtuzumab vs no TCD) among groups in terms of age, sex, disease stage or presence of bulky masses at diagnosis, performance status, interval from diagnosis to SCT, number of previous therapies, use of rituximab pre-SCT or disease status at the time of SCT (Table 1) . Interestingly, the use of peripheral blood as stem cell source was significantly less common in patients receiving ATG compared with the other two groups. Sustained engraftment was observed in 160 (98%) patients, with no significant differences among groups. One patient had a primary graft failure, one patient had a secondary graft failure and two patients died prematurely owing to transplant-related toxicity. Acute GVHD was documented in 65 (40%) of patients at a median of 33 (8-97) days post-SCT, and was grades II-IV in 38 (24%) of them ( Table 2 ). The incidence of grade II-IV acute GVHD was significantly lower in patients undergoing in vivo TCD (17%) compared with patients not receiving any T-cell depleting agent (31%) (P ¼ 0.04). Chronic GVHD was observed in 51% of patients at a median of 5 (3-50) months post-SCT. Chronic GVHD was recorded as limited in 30 (45%) patients and extensive in 36 (55%) patients. Patients in the TCD group had a significantly lower chronic GVHD incidence (33%) compared with non-TCD patients (73%) (Po0.01; Table 2 ). Donor lymphocyte infusions (DLI) were administered to 34 (21%) patients. DLI were significantly more common in TCD compared with non-TCD patients (33 vs 7%; Po0.001). When alemtuzumab and ATG patients were analyzed separately, DLI were also more frequently administered in the alemtuzumab group compared with the ATG group (50 vs 17%; Po0.001). Reasons for DLI were not significantly different among groups (Supplementary Table 1 ).
The cumulative incidence of NRM was 14 and 17% at 1 and 3 years, respectively. Causes of death were equally distributed among groups (Supplementary Table 2 ). Multivariate analysis revealed that disease status at the time of SCT was the only factor significantly associated with NRM (hazard ratio 5.23 (95% confidence interval (CI) 1.6-17.0); P ¼ 0.006), whereas age 450 years was of marginal significance (HR 1.96 (0.87-4.43); P ¼ 0.1). However, TCD had no significant impact on NRM ( Figure 1a , Table 2 ). Thus far, 37 (23%) patients have relapsed at a median of 7 months post-SCT (range 1-39 months). TCD patients had a significantly higher relapse rate (28 vs 14% at 3 years, P ¼ 0.05; Figure 1b , Table 2 ). By multivariate analysis, the strongest predictor of relapse was refractory/ progressive disease at the time of the procedure (HR 7.35 (2.5-21.6); Po0.001), but TCD was also significant (HR 2.20 (1.05-4.59); P ¼ 0.036).
Estimates of PFS were 62% (95% CI 55-70%) and 58% (50-66%) at 2 and 5 years, respectively, for the entire cohort. By univariate analysis, patients receiving alemtuzumab had the lowest 3-year PFS (44%) compared with those receiving ATG (55%) or no TCD (67%) (P ¼ 0.017). This difference remained significant when ATG and alemtuzumab (that is, TCD) patients were pooled together and compared with those not receiving any TCD (P ¼ 0.015; Figure 2a) . By multivariate analysis, disease status at transplantation was the only variable associated with PFS (HR 5.6 (2.4-12.8); Po0.001), although there was also a trend toward statistical significance for TCD (HR 1.6 (0.9-2.7); P ¼ 0.084). Furthermore, TCD was associated with a shorter current PFS by univariate (P ¼ 0.03; Figure 2b ), but not by multivariate analysis.
The OS of the entire cohort was 76% (69-82%) and 72% (64-79%) at 2 and 5 years, respectively. With regard to the use of TCD, there were no differences at any given time point (Table 2, Figure 2c) . As with NRM, relapse rate or PFS, the only factor with a significant impact on OS was disease status at transplantation (HR 7.37 (2.9-18.7); Po0.001). When acute GVHD was included as a time-dependent covariate in a Cox regression analysis, it was significantly predictive of a higher NRM (HR 3.02 (1.3-7-0); P ¼ 0.01) and a lower relapse rate (HR 4.06 (1.23-13.35); P ¼ 0.02). When grade II-IV acute GVHD was analyzed, the effect was even more patent on NRM (HR 5.84 (2.5-13.6); Po0.001), but less so on relapse (P ¼ 0.16). Chronic GVHD was predictive of a lower relapse rate (HR 2.65 (1.04-6.77); P ¼ 0.04) when evaluated as a timedependent covariate. These results were confirmed by a landmark analysis performed at 9 months (P ¼ 0.02; Figure 3 ).
In conclusion, the only factor that emerged as truly predictive of all outcomes was disease status at transplantation. Patients with progressive/refractory disease had a significantly higher relapse rate and NRM, and also a significantly shorter PFS, current PFS and OS. This issue has been already raised by other authors, 4, 7 suggesting that it would be reasonable to either select patients for allo-SCT earlier in their disease course or administer novel salvage approaches to control the disease before proceeding to transplantation. Both alemtuzumab and ATG were effective in reducing acute and chronic GVHD, but had no significant impact on NRM. The low GVHD rates detected in TCD patients are consistent with previous reports using alemtuzumab. 5 Also, the chronic GVHD rate obtained in Letters to the Editor non-TCD patients is very similar to that observed in similar studies. 4, 8 These facts make us believe that these differences in GVHD rates observed in our study are genuine. However, this beneficial effect on GVHD was counterbalanced by a higher relapse rate and a trend toward a shorter PFS. Of note, patients undergoing TCD transplants did not have a higher incidence of primary or secondary graft failure, infectious deaths or post-transplant lymphoproliferative disease (Supplementary  Table 2 ). Furthermore, NRM was remarkably low, o20% at 3 years, in all study groups, and the differences observed in PFS did not translate into a significantly different OS, possibly suggesting that a good proportion of patients relapsing after allo-SCT could be salvaged with DLI or other alternative therapeutic approaches. Therefore, TCD is generally not recommended for FL patients undergoing RIC allo-SCT from HLA-identical siblings, although its role could be further clarified by ongoing prospective trials. On the other hand, TCD could be more beneficial for FL patients undergoing RIC allo-SCT from alternative donors, and should be the subject of future studies.
Finally, we would like to acknowledge that the conclusions drawn from any retrospective analysis are less compelling than those extracted from a randomized prospective study. However, in the absence of the latter, retrospective analyses may provide adequate data to continue improving our clinical practice. It could be argued that the statistical power of the study was suboptimal as the ATG, alemtuzumab and non-TCD groups had a relatively small number of patients. Also, several factors, such as the alkylating agent (melphalan vs busulfan vs cyclophosphamide) and the stem cell source (bone marrow vs peripheral blood) were not evenly distributed among groups and could have confounded our results. However, we preferred to have small cohorts of patients receiving unmanipulated grafts from the same type of donor after similar conditioning regimens rather than larger but more heterogeneous cohorts receiving diverse regimens and stem cell grafts.
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